Please login to the form below

Not currently logged in
Email:
Password:

Pharmalink appoints new chairman Anders Wiklund

The Swedish specialty pharma company has also appointed Elisabeth Lindner to its board of directors

Anders Wiklund has joined Swedish specialty pharma company Pharmalink AB as chairman of the board.

He previously spent 29 years with the Kabi and Pharmacia group of companies, holding roles such as UK managing director of KabiVitrum, president of KabiVitrum International in Sweden, president and CEO of KabiVitrum and KabiPharmacia in the US.

In his new role Wiklund, who currently serves on the boards of QuatRX, EffRx, Clavis Pharma and Life Medical, will take over from Pharmalink's outgoing chairman Bengt Julander.

Julander, who founded the company in 1991, will remain on Pharmalink's board as a non-executive director, as will Lennart Hansson.

In Hansson's place on the board of directors Pharmalink has appointed Elisabeth Lindner, who joins from fellow Swedish pharmaceutical company Diamyd Medical AB.

"With Anders taking on the Chairman's role and Elisabeth joining the Board, Pharmalink is positioned for the next stage of development," said Johan Haggblad, managing director of Pharmalink.

"Anders' and Elisabeth's exceptional industry experience will be invaluable in ensuring we realise value for Pharmalink and for patients with significant unmet medical need."

15th November 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics